HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): O. Wayne Isom Todd K. Rosengart Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, L. Y. Articles by Rosengart, T. K. Search for Related Content PubMed PubMed Citation Articles by Lee, L. Y. Articles by Rosengart, T. K.

Ann Thorac Surg 2000;70:498-503
© 2000 The Society of Thoracic Surgeons

---

Original articles: cardiovascular

Transmyocardial laser revascularization with excimer laser: clinical results at 1 year

^a Department of Cardiothoracic Surgery, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York, USA
^b Cardiology, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York, USA
^c Nuclear Cardiology, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York, USA

Address reprint requests to Dr Rosengart, Evanston Northwestern Healthcare, 2650 Ridge Ave, Burch 100, Evanston, IL 60201
e-mail: trosengant{at}enh.org

Background. Transmyocardial laser revascularization, a new strategy for the treatment of diffuse ischemic heart disease, uses laser technology for the theoretical purpose of forming transmyocardial channels in the heart to increase perfusion to ischemic zones. This report summarizes our initial clinical experience with the procedure.

Methods. Excimer transmyocardial laser revascularization was performed in a reversibly ischemic region of the heart in 15 patients. Ischemia and myocardial viability were evaluated by assessment of symptoms and of results of radionuclide single photon emission computed tomography imaging, exercise tolerance testing, and 24-hour Holter monitoring.

Results. No adverse events occurred as a result of the laser revascularization, although 1 patient with preoperative ventricular arrhythmias died 48 hours postoperatively as a result of refractory ventricular tachycardia. Angina class decreased significantly from base line values in patients who had undergone the procedure (mean Canadian Cardiovascular Association angina class, 3.5 ± 0.5 at base line, 1.6 ± 0.6 at 1 month, 1.5 ± 0.8 at 3 months, 1.9 ± 0.9 at 6 months, 1.8 ± 0.8 at 12 months; p < 0.002), and nitroglycerin requirements were similarly decreased in patients who had undergone laser revascularization (mean g/wk of sublingual nitroglycerin, 19 ± 4 at baseline, 5 ±3 at 1 month, 4 ± 2 at 3 months, 4 ± 2 at 6 months, 2 ± 1 at 12 months; p <0.02). Exercise tolerance testing demonstrated increase in exercise duration compared with base line values (mean minutes, 7.4 ± 3.1 at base line, 8.0 ± 3.9 at 1 month, 8.5 ± 4.4 at 3 months, and 9.0 ± 3.9 at 12 months; p >0.05); those increases were not large enough to be statistically significant, however.

Conclusions. Our data are consistent with the concept that excimer transmyocardial laser revascularization in individuals with significant ischemic heart disease appears to be well tolerated, can be performed safely, and may lead to a reduction in ischemic symptomatology.

This article has been cited by other articles:

				M. B. Leon, R. Kornowski, W. E. Downey, G. Weisz, D. S. Baim, R. O. Bonow, R. C. Hendel, D. J. Cohen, E. Gervino, R. Laham, et al. A Blinded, Randomized, Placebo-Controlled Trial of Percutaneous Laser Myocardial Revascularization to Improve Angina Symptoms in Patients With Severe Coronary Disease J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1812 - 1819. [Abstract] [Full Text] [PDF]

				J. A. P. van der Sloot, M. Huikeshoven, R. Tukkie, H. J. Verberne, J. van der Meulen, B. L. F. van Eck-Smit, M. J. C. van Gemert, J. G. P. Tijssen, and J. F. Beek Transmyocardial revascularization using an XeCl excimer laser: Results of a randomized trial Ann. Thorac. Surg., September 1, 2004; 78(3): 875 - 881. [Abstract] [Full Text] [PDF]

				C. R. Bridges, K. A. Horvath, W. C. Nugent, D. M. Shahian, C. K. Haan, R. J. Shemin, K. B. Allen, and F. H. Edwards The Society of Thoracic Surgeons practice guideline series: transmyocardial laser revascularization Ann. Thorac. Surg., April 1, 2004; 77(4): 1494 - 1502. [Abstract] [Full Text] [PDF]

				J. F. Beek, J. A. P. van der Sloot, M. Huikeshoven, H. J. Verberne, B. L. F. van Eck-Smit, J. van der Meulen, J. G. P. Tijssen, M. J. C. van Gemert, and R. Tukkie Cardiac denervation after clinical transmyocardial laser revascularization: Short-term and long-term iodine 123-labeled meta-iodobenzylguanide scintigraphic evidence J. Thorac. Cardiovasc. Surg., February 1, 2004; 127(2): 517 - 524. [Abstract] [Full Text] [PDF]

				M. Saririan and M. J. Eisenberg Myocardial laser revascularization for the treatment of end-stage coronary artery disease J. Am. Coll. Cardiol., January 15, 2003; 41(2): 173 - 183. [Abstract] [Full Text] [PDF]

				M. Ruel, R. A. Kelly, and F. W. Sellke Therapeutic Angiogenesis, Transmyocardial Laser Revascularization, and Cell Therapy Card. Surg. Adult, January 1, 2003; 2(2003): 715 - 750. [Full Text]

				A. H. Hamawy, L. Y. Lee, S. A. Samy, D. R. Polce, M. Szulc, M. Vazquez, and T. K. Rosengart Transmyocardial laser revascularization dose response: enhanced perfusion in a porcine ischemia model as a function of channel density Ann. Thorac. Surg., September 1, 2001; 72(3): 817 - 822. [Abstract] [Full Text] [PDF]